Literatura ACTA MEDICINAE 10 11/2018 Onkologie Hematoonkologie

Transkript

1 Literatura 3 Imunoterapie nemalobuněčných karcinomů plic současný stav a budoucnost prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha 3 Léčba karcinomu plic aktuálně a výhledy MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha 4 Poslední výsledky analýzy dat klinické studie ALEX (data cut-off 12/2017) MUDr. Daniel Krejčí Klinika pneumologie a hrudní chirurgie, Nemocnice na Bulovce, Praha 4 Studie APHINITY: Adjuvantní léčba zachraňuje životy prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň 4 Dočkají se naše nemocné? Léčba pokročilého karcinomu prsu inhibitory CDK4/6 MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno 4 Pertuzumab v neoadjuvantní léčbě karcinomu prsu MUDr. Markéta Protivánková Interní hematologická a onkologická klinika, LF MU a FN Brno 4 Je čas na změnu algoritmu léčby pokročilého karcinomu ledviny? prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK Plzeň 5 Pacientka s pokročilým gastrointestinálním stromálním nádorem léčeným sunitinibem kazuistika MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha 5 Levá a pravá význam lokalizace primárního nádoru u kolorektálního karcinomu MUDr. Michal Vočka prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika, VFN a 1. LF UK, Praha 5 Studie PRECONNECT: Přínos trifluridin/tipiracilu u pacientů s metastatickým kolorektálním karcinomem MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno 5 Teysuno v léčbě metastatického karcinomu žaludku MUDr. Radka Obermannová, Ph.D. Klinika komplexní onkologické péče, MOÚ a MU, Brno 5 Ramucirumab cílený zásah jaterních metastáz karcinomu gastroezofageální junkce kazuistika MUDr. Sabina Svobodová MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně MUDr. Adam Peštál, Ph.D. I. chirurgická klinika, FN u sv. Anny v Brně MUDr. Igor Suškevič Klinika zobrazovacích metod, FN u sv. Anny v Brně 6 Monoterapie, nebo kombinovaná léčba inhibitory kontrolních bodů imunity v první linii léčby pacientů s metastazujícím melanomem? MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 6 Léčba generalizovaného maligního melanomu kombinací BRAF inhibitoru dabrafenibu s MEK inhibitorem trametinibem kazuistika MUDr. Michaela Fridrichová Ústav radiační onkologie Nemocnice Na Bulovce, Praha 6 Pacient s mnohočetným recidivujícím bazocelulárním karcinomem kazuistika MUDr. Renata Emmerová Komplexní onkologické centrum, KN Liberec, a. s., Liberec 6 Lenvatinib nově dostupná možnost léčby radiojod refrakterního diferencovaného karcinomu štítné žlázy MUDr. Hana Švébišová, Ph.D. Onkologická klinika a LF UP, Olomouc 6 Kam směřuje léčba chronické myeloidní leukemie inhibitory tyrosinové kinázy? MUDr. Hana Klamová, Ph.D. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha 7 Hodgkinův lymfom u starších nemocných MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF UK, Praha 8 Můžeme upravit intenzitu úvodní léčby u Hodgkinova lymfomu podle výsledku průběžného PET? doc. MUDr. Vít Procházka, Ph.D. MUDr. Marie Lukášová Hemato-onkologická klinika Fakultní nemocnice Olomouc MUDr. Lenka Henzlová, Ph.D. Klinika nukleární medicíny Fakultní nemocnice Olomouc prof. MUDr. Tomáš Papajík, CSc. Hemato-onkologická klinika Fakultní nemocnice Olomouc

2 8 Primární lymfom centrální nervové soustavy kam kráčíš? MUDr. Heidi Móciková, Ph.D. Interní hematologická klinika FNKV a 3. LF UK, Praha 8 Úspěšná léčba obinutuzumabem s chlorambucilem u staršího pacienta s masivní lymfadenopatií kazuistika MUDr. Martin Špaček, Ph.D. I. interní klinika klinika hematologie 1. LF UK a VFN, Praha 9 Úspěšná léčba venetoklaxem u pacientky s abruptivním relapsem předléčené relabující/refrakterní chronické lymfocytární leukemie po selhání terapie idelalisibem a ibrutinibem kazuistika MUDr. Peter Turcsányi, Ph.D. MUDr. Renata Urbanová, Ph.D. prof. MUDr. Tomáš Papajík CSc. Hemato-onkologická klinika FN Olomouc 9 Aktuální léčba relabované a refrakterní chronické lymfocytární leukemie kazuistika MUDr. Martin Šimkovič, Ph.D. IV. interní hematologická klinika, FN Hradec Králové 9 Management lymfomů v těhotenství MUDr. Jan Kořen I. interní klinika klinika hematologie, 1. LF UK a VFN, Praha 9 Příznivý vliv dasatinibu na kompenzaci diabetu u pacienta s chronickou myeloidní leukemií kazuistika MUDr. Petra Bělohlávková, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové 10 Nová doporučení pro léčbu chronické lymfocytární leukemie a ibrutinib MUDr. Jakub Trizuljak prof. MUDr. Michael Doubek, Ph.D. Interní hematologická a onkologická klinika, LF a FN Brno, Středoevropský technologický institut (CEITEC) Masarykovy univerzity, Brno

3 Imunoterapie nemalobuněčných karcinomů plic současný stav a budoucnost prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika 1. LF UK a VFN, Praha 1 Brahmer, J. Reckamp, K. L. Baas, P., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015, 373, s Borghaei, H. Paz-Ares, L. Horn, L., et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 201, 373, s Herbst, R. S. Baas, P. Kim, D. W., et al.: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387, s Rittmeyer, A. Barlesi, F. Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389, s Kim, J. M. Chen, D. S.: Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). An Oncol, 2016, 27, s Chen, D. S. Mellamn, I.: Elements of cancer imunity and the cancerimmune set point. Nature, 2017, 541, s Hegde, P. S. Karanikas, V. Evers, S.: The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res, 2016, 22, s Gandhi, L. Rodríguez-Abreu, D. Gadgeel S, et al.; Keynote-189 investigators: Pembrolizumab plus chemotherapy in metastatic nonsmall-cell lung cancer. N Engl J Med, 2018, 378, s , doi: /NEJMoa Socinsky, M. A. Jotte, R. M. Frederico Cappuzo, M. D., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018, 378, s Hellmann, M. D. Ciuleanu, T-E. Pluzanski, A., et al.: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med, 2018, 378, s Melosky B.: Current treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer. Mini review article. Front Oncol, , 12 Reck, M. Rodrígues-Abreu, D. Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375, s Lopes, G. Wu, Y. Kudaba, I., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol, 2018, 36, suppl., abstrakt LBA4. 14 Paz-Ares, L. Luft, A. Tafreshi, A., et al.: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). J Clin Oncol, suppl., 2018, ascopubs.org/doi/abs/ /jco _suppl Carbone, D. P. Reck, M. Paz-Ares, L., et al.: First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med, 2017, 376, s Borghaei, H. Paz-Ares, L. Horn, L., et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373, s. 1627, doi: /NEJMoa ; J Clin Oncol, suppl., Léčba karcinomu plic aktuálně a výhledy MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha 1 Scagliotti, G. V., et al.: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26, s Yang, J. C., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. Abstrakt 943, přednáška. Prezentováno na 16 th World Conference on Lung Cancer, , Denver, CO. 3 Mitsudomi, T., et al.: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 Phase II study. Abstrakt 1406, přednáška. Prezentováno na 16 th World Conference on Lung Cancer, , Denver, CO. 4 Mok, T. S. Wu, Y. L. Ahn, M. J., et al.: Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376, s Soria, J. C. Ohe, Y. Vansteenkiste, J., et al.: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018, 378, s Vansteenkiste, J. Reungwetwattana, T. Nakagawa, K., et al.: CNS response to osimertinib vs standard-of-care EGFR-TKI as firstline treatment in patients with EGFRm advanced NSCLC: FLAURA. Prezentováno na European Society of Medical Oncology Asia Congress, , Singapur, abstrakt LBA5. 7 Thatcher, N. Hirsch, F. R. Luft, A. V., et al.: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncology, 2015, 16, s Soria, J. C. Tan, D. S. Chiari, R., et al.: First-line ceritinib versus platinum based chemotherapy in advanced ALK-rearranged nonsmall cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, Epub Shaw, A. T. Kim, T. M. Crinò,L., et al.: Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet, 2017, 18, s Gettinger, S. N. Bazhenova, L. A. Langer, C. J., et al.: Activity and safety of brigatinib in ALK-rearranged non-small cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol, 2016, 17, s Camidge, D. Tiseo, M. Ahn, M., et al.: Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial. Prezentováno na 17 th World Conference on Lung Cancer, prosinec 2016, Vídeň, Rakousko. 12 Solomon, B., et al.: Phase 2 study of lorlatinib in patients with advanced ALK+ /ROS1+ non-small-cell lung cancer. Prezentováno na International Association for the Study of Lung Cancer (IASLC) 18 th World Conference on Lung Cancer, , abstrakt #OA Novello, S. Mazières, J. Oh, I.-J., et al.: Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)- positive non-small-cell lung cancer: results from the phase III ALUR study. An Oncol, mdy121, 14 Solange, P. Ross Camidge, D. Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017, 377, s Camidge, D. R., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt Shaw, A. T., et al.: Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014, 371, s Ahn, M.-J. Cho, B. C. Siena, S., et al.: Entrectinib in patients with locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). Prezentováno na IASLC 18 th World Conference on Lung Cancer, , Jokohama, Japonsko, abstrakt Drilon, A. De Braud, F. G. Siena S, et al.: Entrectinib, an oral pan- Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements. Prezentováno na AACR Annual Meeting, , New Orleans, Louisiana, abstrakt CT Sandler, A., et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. NEJM, 2006, 355, s Reck, M. Kaiser, R. Mellemgaard, A., et al.: LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME- Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol, 2014, 15, s , doi: /S (13) , Epub Garon, E. B. Ciuleanu, T-E. Arrieta, O., et al.: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 2014, 384, s Seto, T. Kato, T. Nishio, M., et al.: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO 25567): an open-label,randomised, multicentre, phase 2 study. Lancet Oncol, 2014, 15, s Brahmer, J. R. Rodriguez-Abreu, D. Robinson, A. G., et al.: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) 50% enrolled in KEYNOTE ASCO Annual Meeting. J Clin Oncol, 2017, 35, suppl., abstrakt Spigel, D. R., et al.: A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol, 2015, 33, suppl., abstrakt Paz-Ares, L. Horn, L. Borghaei, H., et al.: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-sq) non-small cell lung cancer (NSCLC). J Clin Oncol, 2015, 33, suppl., abstrakt LBA Horn, L. Spigel, D. R. Vokes, E. E., et al.: Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase iii trials (CheckMate 017 and CheckMate 057). J Clin Oncol, 2017, 35, s Herbst, R. S. Kim, D.-W. Felip, E., et al.: KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy. Prezentováno na ESMO Asia 2015 Congress, Singapur, , LBA3 PR. 28 Rittmeyer, A. Barlesi, F. Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389, s Papadimitrakopoulou, V. Gadgeel, S. M. Borghaei, H., et al.: Firstline carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G. J Clin Oncol, 2017, 35, suppl., s , DOI: /JCO _suppl Gandhi, L. Rodríguez-Abreu, D. Gadgeel, S., et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med, Reck, M., et al.: Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IM- POWER150). An Oncol, 2017, 28, suppl. 11, , mdx Socinski, M. A., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med, 2018, 378, s Borghaei, et al.: Nivolumab + ipilimumab, nivolumab + chemotherapy, and chemotherapy in chemo-naive patients with advanced nonsmall cell lung cancer and < 1 % tumor PD-L1 expression: results from CheckMate 227. Prezentováno na ASCO 2018 Meeting (přednáška). 34 Jotte, R. M. Cappuzzo, F. Vynnychenko, I., et al.: IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt LBA Scott, J. A. Bendell, J. C. Tailor, M. H., et al.: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA J Clin Oncol, 2015, 33, suppl., abstrakt 7503). 36 Hellmann, M. D. Ciuleanu, T. E. Pluzanski, A., et al.: Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med, 2018, 378, s Scott, J. A. Villegas, A. Daniel, D., et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, November 16, N Engl J Med, 2017, 377, s Antonia, S. J. Villegas, A. Daniel, D., et al.: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [article and supplementary appendix]. N Engl J Med, 2017, 377, s Hellmann, M. D. Callahan, M. K. Awad, M. M., et al.: Tumor mutation burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small cell lung cancer. Cancer Cell, 2018, 33, s Camidge, D. R., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. NCT , ASCO J Clin Oncol, 2018, 36, suppl., abstrakt Brahmer, J., et al.: Updated analysis of KEYNOTE-024: Pembrolizumab vs platinum-based chemotherapy for advanced NSCLC with PD- L1 TPS 50%. Prezentováno na WCLC 2017, abstrakt OA J Thor Oncol, 2017, 12, suppl. 2, s. S1793 S1794, jtho Lopes, G. Wu Y.-L. Kudaba, I., et al.: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) 1%: Open-label, phase 3 KEYNOTE-042 study. Prezentováno na ASCO J Clin Oncol, 2018, 36, suppl., abstrakt LBA4. 43 Paz-Ares, L. G. Luft, A. Tafreshi, A., et al.: Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC). Prezentováno na ASCO J Clin Oncol, 2018, 36, suppl., abstrakt Socinski, M. A. Jotte, R. M. Cappuzzo, F., et al.: Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. J Clin Oncol, 2018, 36, suppl., abstrakt 9002.

4 Poslední výsledky analýzy dat klinické studie ALEX (data cut-off 12/2017) MUDr. Daniel Krejčí Klinika pneumologie a hrudní chirurgie, Nemocnice na Bulovce, Praha 1 Skřičková, J. Kolek, V., et al.: Základy moderní pneumoonkologie. Maxdrof Jesenius, 2017, s Rangachari, D. Yamaguchi, N. Van der Laan, P. A., et al.: Brain metastases in patients with EGFR-mutated or ALK-rearranged nonsmall-cell lung cancers. Lung Cancer, 2015, s. 88: Peters, S. Camidge, D. R. Shaw, A. T., et al.: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med, 2017, 377, s SPC Alectinib. 5 Camidge, D. R. Peters, S. Mok, T., et al.: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. ASCO J Clin Oncol, 2018, 36, suppl., abstrakt Novello, S. Barlesi, F., et. al.: Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Publikováno Ann Oncol, 2016, 27, suppl. 5, v1 v Studie APHINITY: Adjuvantní léčba zachraňuje životy prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika FN a LF UK Plzeň 1 Minckwitz, G. Procter, M. Azambuja, E., et al.: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med, 2017, 377, s , doi: /NEJMoa , Epub Dočkají se naše nemocné? Léčba pokročilého karcinomu prsu inhibitory CDK4/6 MUDr. Miloš Holánek Klinika komplexní onkologické péče, MOÚ, Brno 1 Baselga, J., et al.: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New Eng J Med, 2012, 366, s Fasching, P. A., et al.: Breast cancer treatment with everolimus and exemestane for ER+ women-results of the 2 nd interim amalysis of the non-interventional trial brawo. An Oncol, 2014, 25, suppl. 4, mdu Finn, R. S., et al.: Abstract CT101: Final results of a randomized Phase II study of PD , a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2 advanced breast cancer (PALOMA-1; TRIO-18). Cancer Research, 2014, 74, suppl., CT Finn, R. S., et al.: Palbociclib and letrozole in advanced breast cancer. New Eng J Med, 2016, 375, s Cristofanilli, M., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17, s Finn, R. S., et al.: Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontone treatment of ER+/HER2 advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol, 2017, 35, suppl. 1001, DOI: / JCO _suppl Hortobagyi, G. N., et al.: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New Eng J Med, 2016, 375, s Hortobagyi, G. N., et al.: Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptorpositive (HR+), HER2-negative (HER2 ), advanced breast cancer (ABC). Ann Oncol, 2018, 29, s , doi: /annonc/mdy Slamon, D. J., et al.: Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, JCO , doi: /JCO Didkler, M. N., et al.: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2 breast cancer, after chemotherapy for advanced disease. J Clin Oncol, 2016, 34, suppl. 510, DOI: / JCO _suppl Goetz, M. P., et al.: MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol, 2017, 35, s , doi: /JCO , Epub Sledge, J. R. George, W., et al.: MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol, 2017, 35, s Pertuzumab v neoadjuvantní léčbě karcinomu prsu MUDr. Markéta Protivánková Interní hematologická a onkologická klinika, LF MU a FN Brno 1 Teshome, M. Hunt, K. K.: Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am, 2014, 23, s Vyzula, R., et al.: Modrá kniha ČOS ČLS JEP. Aktualizace: 24. Brno, Masarykův onkologický ústav. 3 Perez, E. A. Romond, E. H. Suman, V. J., et al.: Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 2014, 32, s Gianni, L. Eiermann, W. Semiglazov, V., et al.: Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer: a randomised controlled superiority trial with a parallel HER2-negative cohort (the NOAH trial). Lancet, 2010, 375, s Gianni, L. Eiermann, W. Semiglazov, V., et al.: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol, 2014, 15, s Fendly, B. M. Winget, M. Hudziak, R. M., et al.: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res, 1990, 50, s Gianni, L. Pienkowski, T. Im, Y. H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13, s Gianni, L. Pienkowski, T. Im, Y. H., et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17, s Schneeweiss, A. Chia, S. Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). An Oncol, 2013, 24, s Untch, M. Jackisch, C. H. Schneeweiss, A., at al.: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto GBG 69). Lancet Oncol, 2016, 17, s Schneeweiss, A. Chia, S. Hickish, T., et al.: Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Lancet Oncol, 2016, 17, s Swain, S. V. Ewer, M. S. Viale, G., et al.: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. An Oncol, 2018, 29, s Baselga, J. Swain, S. M.: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer, 2009, 9, s Gianni, L. Pienkowski, T. Im, Y.-H., et al.: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neo- Sphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13, s Schneeweiss, A. Chia, S. Hickish, T., et al.: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 2013, 24, s A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Earlystage Breast Cancer. NCT Dostupné z: gov/ct2/show/nct , vyhledáno , ClinicalTrials.gov Identifier: NCT Je čas na změnu algoritmu léčby pokročilého karcinomu ledviny? prof. MUDr. Jindřich Fínek, Ph.D. Onkologická a radioterapeutická klinika FN a LF UK Plzeň 1 Motzer, R. J. Tannir, N. M. McDermott, D. F., et al.: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. NEJM, , dostupné z: NEJM.org. 2 Escudier, B. Sharma, P. McDermott, D. F., et al.: CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol, 2017, 72, s , doi: /j. eururo , Epub

5 Pacientka s pokročilým gastrointestinálním stromálním nádorem léčeným sunitinibem kazuistika MUDr. Zdeněk Linke Onkologická klinika 2. LF UK a FN v Motole, Praha 1 Heindrich, M. C. Maki, R. G. Corless, C. L., et al.: Sunitinib response in imatinib-esistant GIST correlates with KIT and PDGFR mutation status. J Clin Oncol, 2006, 24, s Demetri, G. D. van Oosterom, A. T., et al.: Efficacy and safety of sunitinib in patients with advanced gastointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, s Levá a pravá význam lokalizace primárního nádoru u kolorektálního karcinomu MUDr. Michal Vočka prof. MUDr. Luboš Petruželka, CSc. Onkologická klinika, VFN a 1. LF UK, Praha 1 Hutchins, G. Southward, K. Handley, K., et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J ClinOncol, 2011, 29, s Henrichsen-Schnack, T. Ladelund, S. Nilbert, M.: The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-egfr treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol, 2014, 53, s Petrelli, F. Tomasello, G. Borgonovo, K., et al.: Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncology, 2017, 3, s Dienstmann, R.: Tumor side as model of integrative molecular classification of colorectal cancer. Clin Cancer Res, 2018, 24, s Shimada, Y. Kameyama, H. Nagahashi, M., et al.: Comprehensive genomic sequencing detectsim portant genetic differences between right-sided and left-sided colorectal cancer. Oncotarget, 2017, 8, s Salem, M. E. Weinberg, B. A. Xiu, J., et al.: Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, s Guinney, J. Dienstmann, R. Wang, X., et al.: The konsensus molecular subtypes of colorectal cancer. Nat Med, 2015, 21, s Pugh, S. A. Shinkins, B. Fuller, A., et al.: Site and stage of colorectal cancer influence the likelihood and distribution of disease recurrence and postre currence survival: data from the FACTS randomized controlled trial. Ann Surg, 2016, 263, s Arnold, D. Lueza, B. Douillard, J. Y., et al.: Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Med Oncol, 2017, 28, s Holch, J. W. Ricard, I. Stintzing, S., et al.: The relevance of primary tumour location in patients with metastatic colorectal cancer: a metaanalysis of first-line clinical trials. Eur J Cancer, 2017, 70, s Tejpar, S. Stintzing, S. Ciardiello, F., et al.: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol, 2017, 3, s Hibberd, A. A. Lyra, A. Ouwehand, A. C., et al.: Intestinal microbiota altered in patients with colon cancer and modified by probiotic intervention. BMJ open Gastroenterol, 2017, 4, s. e Mima, K. Nishihara, R. Qian, Z. R., et al.: Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut, 2016, 65, s Lee, G. H. Malietzis, G. Askari, A., et al.: Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol, 2015, 41, s Studie PRECONNECT: Přínos trifluridin/tipiracilu u pacientů s metastatickým kolorektálním karcinomem MUDr. Beatrix Bencsiková, Ph.D. Klinika komplexní onkologické péče, Regionální centrum aplikované molekulární onkologie, Masarykův onkologický ústav, Brno 1 Falcone, A. Andre, T. Edeline, J., et al.: Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mcrc): Preliminary results from the phase 3b, international, open-label, early-access PRECONNECT study. Abstract O-013. Poster prezentován na ESMO 20 th World Congress on Gastrointestinal Cancer, , Barcelona, Španělsko. 2 Emura, T. Nakagawa, F. Fujioka, A., et al.: An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med, 2004, 13, s Mayer, R. J. Van Cutsem, E. Falcone, A., et al.: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med, 2015, 372, s Yoshino, T. Mizunama, N. Yamazaki, K., et al.: TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol, 2012, 13, s Teysuno v léčbě metastatického karcinomu žaludku MUDr. Radka Obermannová, Ph.D. Klinika komplexní onkologické péče, MOÚ a MU, Brno 1 Lordick, F. Lorenzen, S. Yamada, Y., et al.: Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer, 2014, 17, s Bang, Y. J. Van Cutsem, E. Feyereislova, A., et al.: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376, s Fuchs, C. S. Tomasek, J. Yong, C. J., et al.: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, 2014, 383, s Wilke, H. Muro, K. Van Cutsem, E., et al.: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15, s Okines, A. F. C. McCloud, P. Kang, Y., et al.: Meta-analysis of the REAL-2 and ML17032 trials comparing capecitabine with 5-FU in advanced oesofago gastric cancer. An Oncol, 2008, 19, viii169, abstrakt 513PD. 6 Ajani, J. A. Rodriguez, W. Bodoky, G., et al.: Multicenter phase iii comparison of cisplatin/s-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS Trial. J Clin Oncol, 2010, 28, s Nakamura, M. Yamada, Y. Muro, K., et al.: The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Future Oncol, 2015, 11, s , doi: /fon Ramucirumab cílený zásah jaterních metastáz karcinomu gastroezofageální junkce kazuistika MUDr. Sabina Svobodová MUDr. Jana Katolická, Ph.D. Onkologicko-chirurgické oddělení, FN u sv. Anny v Brně MUDr. Adam Peštál, Ph.D. I. chirurgická klinika, FN u sv. Anny v Brně MUDr. Igor Suškevič Klinika zobrazovacích metod, FN u sv. Anny v Brně 1 Wilke, H. Muro, K. Van Cutsem, E., et al.: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patiens with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol, 2014, 15, s Fuchs, C. S. Tomasek, J. Yong, C. J., et al.: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet Oncol, 2014, 383, s Shitara, K., et al.: Effect of post-discontinuation therapy on survival in metastatic gastric-gastroesophageal junction adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. ASCO, Chicago, červen 2018, poster Bang, Y. J. Van Cutsem, E. Feyereislova, A., et al.: Trastuzumab

6 in combination with chemotherapy versus chemoterapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376, s Staněk, L. Tesařová, P. Gúrlich, R., et al.: Molekulární onkologie v kazuistikách. Current Media, Praha, Klener, P. Klener, P. jr.: Nová protinádorová léčiva a léčebné strategie v onkologii. Grada, Kolektiv autorů: Klinická onkologie. 2017, 30, suppl. 3: Advances in immunotherapy. 8 NCCN Clinical Guidelines in Oncology verze , dostupné z: 9 Modrá kniha České onkologické společnosti, 24. aktualizace, platnost od Souhrn údajů o přípravku Cyramza (ramucirumab ), Eli Lilly 1/2016, dostupné z: Monoterapie, nebo kombinovaná léčba inhibitory kontrolních bodů imunity v první linii léčby pacientů s metastazujícím melanomem? MUDr. Ivana Krajsová, MBA Dermatovenerologická klinika VFN a 1. LF UK, Praha 1 De Coana, Y. P. Wolodarski, M. Poschke, I., et al.: Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanom. Oncotarget, 2017, 8, s Weber, J. S. Gibney, G. Sullivan, R. J., et al.: Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol, 2016, 17, s Hodi, F. S. Chesney, J. Pavlick, A. C., et al.: Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma. Lancet Oncol, 2016, 17, s Wolchok, J. D. Chiarion-Sileni, V. Gonzales, R., et al.: Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Eng J Med, 2017, 377, s Menshawy, A. Eltonob, A. A. Barkat, S. A., et al.: Nivolumab monotherapy or in combination with ipilimumab for metastatic mela noma: systematic review and metaanalysis of randomized controlled trials. Melanoma Res, , doi: /CMR , Epub před tiskem. 6 Long, G. V. Atkinson, V. Cebon, J. S., et al.: Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol, 2017, 18, s Retseck, J. Van der Weele, R. Lin, H. M., et al.: Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immuno Therapy Cancer, 2016, 4, s Chae, Y. K. Arya, A. Iams, W. J., et al.: Current landscape and future of dual anti-ctla4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and nonsmall cell lung cancer (NSCLC). J Immunother Cancer, 2018, 6, s. 39, doi: /s Schadendorf, D. Wolchok, J. D. Hodi, F. S., et al.: Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol, 2017, 35, s Long, G. V. Atkinson, V. Lo, S., et al.: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncology, 2018, 19, s Hellmann, M. D. Callahan, M. K. Awad, M. M., et al.: Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell, 2018, 33, s Léčba generalizovaného maligního melanomu kombinací BRAF inhibitoru dabrafenibu s MEK inhibitorem trametinibem kazuistika MUDr. Michaela Fridrichová Ústav radiační onkologie Nemocnice Na Bulovce, Praha 1 Long, G. V. Stroyakovskiy, D. Gogas, H., et al.: Combined BRAF and MEK inhibition versus BRAF inhibitional one in melanoma. N Engl J Med, 2014, 371, s , doi: /NEJMoa Long, G. V. Flaherty, K. T. Stroyakovskiy, D., et al.: Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol, 2017, 28, s , doi: /annonc/mdx Ugurel, S. Röhmel, J. Ascierto, P. A., et al.: Survival of patients with advanced metastatic melanoma: the impact of novel therapies update Eur J Cancer, 2017, 83, s , doi: /j. ejca Pacient s mnohočetným recidivujícím bazocelulárním karcinomem kazuistika MUDr. Renata Emmerová Komplexní onkologické centrum, KN Liberec, a. s., Liberec 1 Roš, T. Gajić, R. Rajić, N., et al.: Basal cell carcinoma: a frequent challenge. Serb J Dermatol Venerol, 2012, 4, s Alter, M. Hillen, U. Leiter, U., et al.: Current diagnosis and treatment of basal cell carcinoma. CME-Article JDDG, 2015, s Basset-Sequin, N. Hauschield, A. Kuntsfeld, R., et al.: Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open label trial. Eur J Cancer, 2017, 86, s Alfieri, S. Bergamini, C. Granata, R., et al.: Retreatment with vismodegib after progression in advanced basal cell carcinoma: firsttime report of a single-institution experience. Target Oncol, 2018, 13, s Sekulic, A. Migden, M. R. Oro, A. E., et al.: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. New Eng J Med, 2012, s Xie, J. Bartels, M. C. Barton, W. S.: Hedgehog signaling in human cancer. Onco Targets Ther, 2013, 6, s Lenvatinib nově dostupná možnost léčby radiojod refrakterního diferencovaného karcinomu štítné žlázy MUDr. Hana Švébišová, Ph.D. Onkologická klinika a LF UP, Olomouc 1 Vlček, P.: Diferencovaný karcinom štítné žlázy nový pohled na jeho léčbu. Onkologie, 2011, 5. 2 Němec, J. Bílek, R. Zamrazil, V. Dvořák, J. Racek, P. Vlček, P.: The prognostic value of plasma Thyroglobulin at the time of hypothyroidism in the differentiated thyroid cancer. Nukl Med, 1995, 34, A Tuttle, R. M., et al.: Novel concepts for initiating multitargeted kinase inhibitors in radioactiveiodine refractory differentiated toroid cancer. Best Prac Res Clin Endocrinol Metab, 2017, 31, s Brose, S. M., et al.: Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol, 2017, Schlumberger, M., et al.: Lenvatinib versus placebo in radioiodine refractory thyroid cancer. New Eng J Med, 2015, 372, s NCCN guidelines: Thyreoid Cancer, Ver Dostupné z: vyhledáno Kam směřuje léčba chronické myeloidní leukemie inhibitory tyrosinové kinázy? MUDr. Hana Klamová, Ph.D. Ústav hematologie a krevní transfuze, Ústav klinické a experimentální hematologie 1. LF UK, Praha 1 Drucker, B. J. Guilhot, F. O Brien, S. G., et al.: Five-year follow-up patiens receiving imatinib for chronic myeloid leukemia. N Engl J Med, 00, s Hehlmann, R. Hochhaus, A. Baccarani, M., et al.; On behalf of the European Leukemia Net: Chronic myeloid leukemia. Lancet, 2007, 370, s Huang, X. Cortes, J. Kantarjian, H.: Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor. Cancer, 2012, 118, s Baccarani, M. Deininger, M. W. Rosti, G., et al.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: Blood, 2013, 122, s Mayer, J., ed., et al.: Léčebné postupy v hematologii: doporučení České hematologické společnosti ČLS JEP. Praha, Česká hematologická společnost České lékařské společnosti J. E. Purkyně, Rousselot, P. Hughuet, F. Rea, D., et al.: Imatinib mesylate discontinuation on patients with chronic myeloid leukemia in complete molecular remission for more than 2 years. Blood, 2007, 109, s Mahon, F. X. Read, D. Guillhot, J., et al.: Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at last 2 years: the prospective Stop Imatinib (STIM) trial. Lancet Oncol, 2010, 11, s Etienne, G. Read, D. Guilhot, J., et al.: Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol, 2017, 35, s Read, D. Nicolini, F. E. Tulliez, M., et al.: Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the

7 STOP 2G-TKI study. Blood, 2017, 129, s Saussele, S. Richter, J. Hochhaus, A., et al.: The concept of treatment-free remission in chronic myeloid leukemia. Leukemia, 2016, 30, s Saussele, S. Richter, J. Guilhot, J., et al.: First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. Haematologicy, 2014, 99, s Mahon, X. F., et al.: Iterim analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in CML: The EURO-SKI study. Blood, 2014, 124, abstrakt Jabbour, E. Kantarjian, H.: Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol, 2018, 93, s Saussele, S. Richter, J. Guilhot, J., et al.: Discontinuation of tyrosine kinase inhibitor therapyin chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised trial. Lancet Oncol, 2018, 19, s Clark, C. E. Polydoros, F. Apperley, J. F., et al.: De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an iterim analysis of a non-randomised, phase 2 trial. Lancet Haematol, 2017, s Russo, D. Martinelli, G. Malagola, M., et al.: Effect and outcome of policy intermittent treatment imatinib in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, s Ambruzzese, E. Trawinska, M. M. Fabritti, S. M., et al.: Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol, 2016, 9, s Holyoake, L. Vetrie, D.: The chronic myeloid leukemia stem cell: stemming the tide or persistence. Blood, 2017, 129, s Hjorth-Hansen, H. Stentoft, J. Richter, J., et al.: Safety and efficacy of the combination of pegylated-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia, 2016, 30, s Hodgkinův lymfom u starších nemocných MUDr. Alice Sýkorová, Ph.D. IV. interní hematologická klinika, FN a LF UK, Hradec Králové MUDr. Heidi Móciková, Ph.D. Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF UK, Praha 1 Hlavní stránka ÚZIS ČR. Dostupné z: vyhledáno Stark, G. L., et al.: Hodgkin s disease in the elderly: a population-based study. Br J Haematol, 2002, 119, s Erdkamp, F. L. Breed, W. P. Bosch, L. J., et al.: Hodgkin disease in the elderly. A registry-based analysis. Cancer, 1992, 70, s Levis, A., et al.: Probability of cure in elderly Hodgkin s disease patients. Haematologica, 1994, 79, s Mir, R., et al.: Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer, 1993, 71, s Roy, P. Vaughan Hudson, G. Vaughan Hudson, B., et al.: Longterm survival in Hodgkin s disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. Eur J Cancer, 2000, 36, s Pulte, D., et al.: Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol, 2014, 164, s Evens, A. M., et al.: A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood, 2012, 119, s Stamatoullas, A., et al.: Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol, 2015, 170, s Enblad, G. Gustavsson, A. Sundström, C., et al.; Swedish Lymphoma Study Group: Patients above sixty years of age with Hodgkin s lymphoma treated with a new strategy. Acta Oncol, 2002, 41, s van Spronsen, D. J. Janssen-Heijnen, M. L. Breed, W. P., et al.: Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin s disease and non-hodgkin s lymphoma, Ann Hematol, 1999, 78, s Thyss, A. Saada, E. Gastaud, L., et al.: Hodgkin s lymphoma in older patients: an orphan disease? Mediterr J Hematol Infect Dis, 2014, 6, e Guinee, V. F., et al.: The prognosis of Hodgkin s disease in older adults. J Clin Oncol, 1991, 9, s Kim, H. K. Silver, B. Li, S., et al.: Hodgkin s disease in elderly patients (> or =60): clinical outcome and treatment strategies. Int J Radiat Oncol Biol Phys, 2003, 56, s Specht, L. Nissen, N. I.: Hodgkin s disease and age. Eur J Haematol, 1989, 43, s Engert, A., et al.: Hodgkin s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin s Study Group. J Clin Oncol, 2005, 23, s Landgren, O., et al.: Hodgkin s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica, 2003, 88, s Ballova, V., et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin s disease comparing BEACOPP baseline and COPP- ABVD (study HD9elderly). Ann Oncol, 2005, 16, s Hasenclever, D. Diehl, V.: A prognostic score for advanced Hodgkin s disease. International Prognostic Factors Project on Advanced Hodgkin s Disease. N Engl J Med, 1998, 339, s Cuccaro, A., et al.: Prognostic factors in Hodgkin lymphoma. Mediterr J Hematol Infect Dis, 2014, Jagadeesh, D. Diefenbach, C. Evens, A. M.: XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes. Hematol Oncol, 2013, 31, suppl. 1, s Enblad, G. Glimelius, B. Sundström, C.: Treatment outcome in Hodgkin s disease in patients above the age of 60: a population-based study. Ann Oncol, 1991, 2, s Wedelin, C., et al.: Prognostic factors in Hodgkin s disease with special reference to age. Cancer, 1984, 53, s Walker, A., et al.: Survival of the older patient compared with the younger patient with Hodgkin s disease. Influence of histologic type, staging, and treatment. Cancer, 1990, 65, s Levis, A., et al.: VEPEMB in elderly Hodgkin s lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Ann Oncol, 2004, 15, s Armstrong, A. A., et al.: Epstein-Barr virus and Hodgkin s disease: further evidence for the three disease hypothesis. Leukemia, 1998, 12, s Klimm, B. Diehl, V. Engert, A.: Hodgkin s lymphoma in the elderly: a different disease in patients over 60. Oncology (Williston Park, N.Y.), 2007, 21, s ; diksuze 990, 996, 998 passim. 28 Greaves, P., et al.: Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol, 2013, 31, s Kelley, T. W. Pohlman, B. Elson, P., et al.: The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol, 2007, 128, s Sieber, M. Engert, A. Diehl, V.: Treatment of Hodgkin s disease: results and current concepts of the German Hodgkin s Lymphoma Study Group. Ann Oncol, 2000, 11, suppl. 1, s Wildiers, H., et al.: International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol, 2014, 32, s Hurria, A., et al.: Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB J Clin Oncol, 2011, 29, s Puts, M. T. E., et al.: An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol, 2014, 25, s Böll, B., et al.: ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol, 2013, 31, s Böll, B., et al.: Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol, 2013, 31, s Evens, A. M., et al.: The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol, 2013, 161, s Böll, B., et al.: Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood, 2016, 127, s Zallio, F., et al.: Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). Br J Haematol, 2016, 172, s Proctor, S. J., et al.: Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood, 2012, 119, s Halbsguth, T. V., et al.: Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood, 2010, 116, s Engert, A., et al.: Reduced treatment intensity in patients with earlystage Hodgkin s lymphoma. N Engl J Med, 2010, 363, s Behringer, K., et al.: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet, 2015, 385, s Radford, J., et al.: Results of a trial of PET-directed therapy for earlystage Hodgkin s lymphoma. N Engl J Med, 2015, 372, s Raemaekers, J. M. M., et al.: Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol, 2014, 32, s Specht, L., et al.: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys, 2014, 89, s Longo, D. L., et al.: Twenty years of MOPP therapy for Hodgkin s disease. J Clin Oncol, 1986, 4, s Bonadonna, G. Valagussa, P. Santoro, A.: Alternating non-crossresistant combination chemotherapy or MOPP in stage IV Hodgkin s disease. A report of 8-year results. Ann Intern Med, 1986, 104, s Duggan, D. B., et al.: Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin s disease: report of an intergroup trial. J Clin Oncol, 2003, 21, s Bartlett, N. L. Rosenberg, S. A. Hoppe, R. T., et al.: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advancedstage Hodgkin s disease: a preliminary report. J Clin Oncol, 1995, 13, s Hoskin, P. J., et al.: Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN J Clin Oncol, 2009, 27, s Weekes, C. D., et al.: Hodgkin s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol, 2002, 20, s Macpherson, N., et al.: Treatment of elderly Hodgkin s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma, 2002, 43, s Kolstad, A., et al.: Standard CHOP-21 as first line therapy for elderly patients with Hodgkin s lymphoma. Leuk Lymphoma, 2007, 48, s Johnson, P., et al.: Adapted treatment guided by interim PET-CT Scan in advanced Hodgkin s lymphoma. N Engl J Med, 2016, 374, s Younes, A., et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin s lymphoma. J Clin Oncol, 2012, 30, s Younes, A., et al.: Brentuximab vedotin (SGN-35) for relapsed CD30- positive lymphomas. N Engl J Med, 2010, 363, s Chen, R., et al.: Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol, 2017, 35, s Ansell, S. M.: Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res, 2017, 23, s Gopal, A. K., et al.: Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma, 2014, 55, Forero-Torres, A., et al.: Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood, 2015, 126, s Friedberg, J. W., et al.: Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged 60 years with HL. Blood, 2017, doi: /blood Connors, J. M., et al.: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin s lymphoma. N Engl J Med, 2018, 378, s Evens, A. M., et al.: Sequential brentuximab vedotin (Bv) before and after adriamycin, vinblastine, and dacarbazine (Bv-AVD) for older patients with untreated classical Hodgkin lymphoma (chl): Final results from a multicenter phase II study. Blood, 2017, 130, s Younes, A., et al.: Nivolumab for classical Hodgkin s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol, 2016, 17, s Armand, P., et al.: Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol, 2018, 36, s Armand, P., et al.: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab